TY - JOUR
T1 - Long-term success treating inflammatory epiretinal neovascularization with immunomodulatory therapy
AU - Zaguia, Fatma
AU - Marchese, Alessandro
AU - Cicinelli, Maria Vittoria
AU - Miller, Victoria J.
AU - Miserocchi, Elisabetta
AU - Goldstein, Debra A.
N1 - Funding Information:
No funding was received for conducting this study. This study was supported by an Unrestricted Departmental Grant from Research to Prevent Blindness.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: This study aims to report the long-term outcomes of uveitis-associated optic disc and epiretinal neovascularization (NV) treated with immunomodulatory therapy alone. Methods: This is a retrospective, multi-center chart review conducted at Northwestern University (Chicago, IL) and San Raffaele Scientific Institute (Milan, Italy) from 2014 to 2021 of patients with optic disc and/or retinal neovascularization associated with uveitis. The data collected included age at the time of NV detection, gender, medications, and follow-up period. Imaging was reviewed if available. Results: Eight eyes of six patients were identified. The mean age was 22 years (range 10–52 years); the median follow-up was 3 years (range 6 months to 7 years). All eyes presented with active NV at the time of uveitis onset; 7 eyes were treatment-naïve. None had clinical or angiographic evidence of retinal ischemia. All patients received a variable combination of local steroids, systemic steroids, and systemic immunosuppression. Complete resolution of uveitic NV occurred in all eyes within a median of 8 weeks (ranging 2–20 weeks) from initiating treatment. No NV recurrence was noted. Conclusion: Immunomodulatory therapy alone may be successful in achieving long-term control of uveitis-associated NV, without the use of destructive measures.
AB - Purpose: This study aims to report the long-term outcomes of uveitis-associated optic disc and epiretinal neovascularization (NV) treated with immunomodulatory therapy alone. Methods: This is a retrospective, multi-center chart review conducted at Northwestern University (Chicago, IL) and San Raffaele Scientific Institute (Milan, Italy) from 2014 to 2021 of patients with optic disc and/or retinal neovascularization associated with uveitis. The data collected included age at the time of NV detection, gender, medications, and follow-up period. Imaging was reviewed if available. Results: Eight eyes of six patients were identified. The mean age was 22 years (range 10–52 years); the median follow-up was 3 years (range 6 months to 7 years). All eyes presented with active NV at the time of uveitis onset; 7 eyes were treatment-naïve. None had clinical or angiographic evidence of retinal ischemia. All patients received a variable combination of local steroids, systemic steroids, and systemic immunosuppression. Complete resolution of uveitic NV occurred in all eyes within a median of 8 weeks (ranging 2–20 weeks) from initiating treatment. No NV recurrence was noted. Conclusion: Immunomodulatory therapy alone may be successful in achieving long-term control of uveitis-associated NV, without the use of destructive measures.
KW - Immunomodulatory therapy
KW - Inflammatory eye disease
KW - Optic disc neovascularization
KW - Retinal neovascularization
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=85114887097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114887097&partnerID=8YFLogxK
U2 - 10.1007/s00417-021-05396-6
DO - 10.1007/s00417-021-05396-6
M3 - Article
C2 - 34499246
AN - SCOPUS:85114887097
SN - 0721-832X
VL - 260
SP - 553
EP - 559
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 2
ER -